Ovarian tumour screening

Early detection of ovarian cancer is challenging, as the disease may present with few or non-specific symptoms in its initial stages. Therefore, ovarian tumour screening, combined with transvaginal ultrasound and measurement of CA125, HE4, and the ROMA index, plays a vital role in early detection and risk assessment.

Main reasons for using this combination of tests:
 

• Early detection – transvaginal ultrasound enables visualisation of the ovarian structure and helps identify even minor changes, cysts, or tumour-like formations;
• More accurate assessment of tumour characteristics – the tumour markers CA125 and HE4 may be elevated in ovarian cancer and help differentiate between benign and malignant lesions;
• ROMA index – combines the values of CA125 and HE4 with information regarding age/menopausal status to provide a statistical assessment of ovarian cancer risk;
• Timely referral for additional examinations – in case of high risk, the patient can be referred more quickly for appropriate further tests and treatment;
• Providing reassurance – results within the normal range help rule out more serious conditions.

This examination is critical for:

• Women over 35–40 years of age;
• Those with a family history of ovarian or breast cancer;
• Women with persistent lower abdominal symptoms, bloating, or pain of unclear origin;
• Before the initiation of fertility treatment or hormonal therapy.
   

This combined approach provides a much more accurate overview of ovarian health than any single test alone and supports timely, well-informed decision-making. 

The test price includes a transvaginal ultrasound examination and hormone tests for CA-125, HE4, and the ROMA index.